![Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more | Fierce Pharma Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1629811187/SBL_DP_Image.jpg/SBL_DP_Image.jpg?VersionId=7GMY5rNAvWEb4i9uufoPzAFsZD_MlFut)
Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more | Fierce Pharma
![PharmaBoardroom - Korea Pharma News: Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster? PharmaBoardroom - Korea Pharma News: Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster?](https://pharmaboardroom.com/wp-content/uploads/2021/04/korea-latest-pharma-news-970x400.jpg)
PharmaBoardroom - Korea Pharma News: Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster?
![Enzolytics and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies | World Pharma Today Enzolytics and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies | World Pharma Today](https://www.worldpharmatoday.com/wp-content/uploads/press-releases/20118/samsung-biologics-Enzlo.jpg)
Enzolytics and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies | World Pharma Today
![GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio | World Pharma Today GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio | World Pharma Today](https://www.worldpharmatoday.com/wp-content/uploads/news/13391/samsung-biologics-sign-CMO-deal-with-GSK-scaled-1.jpg)